NRx Pharmaceuticals, Inc. (NRXP) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
NRXP EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
NRXP Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 0.0% | -1324.4% | -2336.5% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export NRXP earnings history in CSV or JSON format
Free sign-in required to download data
NRx Pharmaceuticals, Inc. (NRXP) Earnings Overview
As of May 8, 2026, NRx Pharmaceuticals, Inc. (NRXP) reported trailing twelve-month net income of -$38M, reflecting +43.9% year-over-year growth. The company earned $-1.71 per diluted share over the past four quarters, with a net profit margin of -2336.5%.
Looking at the long-term picture, NRXP's historical earnings data spans multiple years. The company achieved its highest annual net income of $408,427 in fiscal 2019.
NRx Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including AXSM (-$188M net income, -28.7% margin), ALTO ($13M net income, 1.5% margin), INMB (-$42M net income, -91866.0% margin), NRXP has room to improve margins relative to the peer group. Compare NRXP vs AXSM →
NRXP Earnings vs Peers
Earnings metrics vs comparable public companies
NRXP Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$29M | -13.9% | -$16M | $-1.34 | -2336.5% | -1324.4% |
| 2024 | -$25M | +16.7% | -$20M | $-2.39 | - | - |
| 2023 | -$30M | +24.2% | -$28M | $-3.98 | - | - |
| 2022 | -$40M | +57.3% | -$44M | $-0.60 | - | - |
| 2021 | -$93M | -79.7% | -$95M | $-7.44 | - | - |
| 2020 | -$52M | -12777.2% | -$22M | $-1.51 | - | - |
| 2019 | $408,427 | +517.9% | $-713,187 | $0.80 | - | - |
| 2018 | $66,101 | +163.0% | -$1M | $0.07 | - | - |
| 2017 | $-105,000 | - | $0 | $-0.12 | - | - |
See NRXP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NRXP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NRXP vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNRXP — Frequently Asked Questions
Quick answers to the most common questions about buying NRXP stock.
Is NRXP growing earnings?
NRXP EPS is $-1.71, with earnings growth accelerating to +43.9%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-38M.
What are NRXP's profit margins?
NRx Pharmaceuticals, Inc. net margin is -2336.5%, with operating margin at -1324.4%. Below-average margins reflect competitive or cost pressures.
How consistent are NRXP's earnings?
NRXP earnings data spans 2017-2025. The accelerating earnings trend is +43.9% YoY. Historical data enables comparison across business cycles.